Patients with type 2 diabetes had a higher adjusted risk of all-cause mortality (HR 1.95) and major adverse cardiovascular events (HR 1.87) compared to No-DM patients.
Does type 2 diabetes worsen prognosis or increase complication rates in patients receiving de novo implantable cardioverter defibrillators compared to patients without diabetes?
In patients receiving de novo ICDs, type 2 diabetes is associated with a nearly twofold increased risk of MACE and all-cause mortality compared to those without diabetes, highlighting the need for aggressive comprehensive risk management.
Absolute Event Rate: 0% vs 0%
Abstract Background Patients with type 2 diabetes have an increased risk of tachyarrhythmias and more frequently require implantable cardioverter defibrillators (ICD) than those without diabetes (No-DM). This study aims to investigate whether there is a difference in the indication, prognosis and complication rates for ICD-implantation between patients with and without type 2 diabetes in different ICD prevention groups. Research design and methods This Swedish retrospective cohort study included patients with de novo ICDs implanted between 2010 and 2021. Data from six national registries were analyzed to compare type 2 diabetes and No-DM patients regarding indications, complications, and outcomes (major adverse cardiovascular events MACE, all-cause mortality). Subgroup analyses compared type 2 diabetes and No-DM by primary (PP) or secondary prevention (SP) ICD indication, and within the type 2 diabetes and No-DM groups (PP vs. SP). Results The study cohort consisted of 12,885 patients, including 2,843 with type 2 diabetes. Patients with diabetes had a mean age of 67.9 years and 85.4% were male, compared with 62.1 years and 78.1% among No-DM patients (both p < 0.0001). PP was more frequent in patients with type 2 diabetes (62.7%) than No-DM (54.4%, p < 0.0001). Ischemic heart disease was the most common etiology in both patients with/without type 2 diabetes (47.7% vs. 32.6%, p < 0.0001). Non-ischemic etiologies were more common in No-DM patients, e.g. dilated cardiomyopathy (15.3% vs. 17.5%, p = 0.007). Type 2 diabetes patients had a higher adjusted risk of all-cause mortality (Hazard ratio 1.95 95% CI: 1.81–2.11) and MACE (1.87 1.71–2.05), with a more pronounced risk in SP than PP. Infection rates were comparable between patients with type 2 diabetes and No-DM (1.1% vs. 1.3%). Conclusions Patients with type 2 diabetes more often received ICDs for PP and ischemic indications than No-DM patients and had a worse prognosis despite similar one-year infection risk. This likely reflects greater comorbidity burden and diabetes-specific factors, indicating the need for tailored risk management strategies beyond device implantation in patients with type 2 diabetes. Graphical Abstract
Zhou et al. (Wed,) reported a other. Patients with type 2 diabetes had a higher adjusted risk of all-cause mortality (HR 1.95) and major adverse cardiovascular events (HR 1.87) compared to No-DM patients.